Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
Christos Haritoglou, Aljoscha S Neubauer, Marcus KerntDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyAbstract: Diabetic macular edema (DME) is a potentially sight-threatening disease that predominantly affects patients with type 2 diabetes. The pathogenesis is complex, wi...
Guardado en:
Autores principales: | Haritoglou C, Neubauer AS, Kernt M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2dc073ad8f77414d931f5eba102fc2d0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series
por: Schmit-Eilenberger VK
Publicado: (2015) -
Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
por: Saedon H, et al.
Publicado: (2017) -
Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
por: Marey HM, et al.
Publicado: (2011) -
Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser
por: Neubauer AS, et al.
Publicado: (2013) -
Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas®)
por: Kampik A, et al.
Publicado: (2012)